Eli Lilly and Company (LLY)
| Market Cap | 679.43B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 49.49 |
| Forward PE | 27.30 |
| Dividend | $6.00 (0.79%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 723,135 |
| Open | 745.41 |
| Previous Close | 748.19 |
| Day's Range | 744.54 - 755.47 |
| 52-Week Range | 623.78 - 939.86 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 981.47 (+29.68%) |
| Earnings Date | Oct 29, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $981.47, which is an increase of 29.68% from the latest price.
News
Focus: Lilly weight-loss pill could be FDA-approved by year-end
Eli Lilly 's experimental weight-loss pill could be fast-tracked under a one- to two-month review process recently launched by the U.S. Food and Drug Administration, several Wall Street analysts said.
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
The oral GLP-1 segment is entering a pivotal stage, with major growth anticipated from 2026 onward. Patient preference for oral pills over injectables is strong, making ease of use a key driver for fu...
GLP-1 obesity pills face off in head-to-head trial
CNBC's Angelica Peebles joins 'Money Movers' to discuss Eli Lilly and Novo Nordisk battle over GLP-1 obesity pills.
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in ...
Eli Lilly loses appeal of $183.7 million Medicaid fraud award
A federal appeals court on Thursday rejected Eli Lilly's appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid.
Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
INDIANAPOLIS , Sept. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025.
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
The Big 3: TGT, LLY, C
Target (TGT) will continue to face challenges with a weakening economy hitting the retail industry, says @Theotrade's Don Kaufman. He says the stock can continue to stumble if it slides below $90.
Trump's Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.
The effort falls well short of banning the ads outright, but could dent sales.
US FDA to step up enforcement of pharma ads, sends enforcement letters
The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi...
Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health
Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations between people and their doctors Nearly four in five Amer...
Eli Lilly launches platform for AI-enabled drug discovery
Drugmaker Eli Lilly said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on years of Lilly's...
Circle Pharma Announces Agreement with Lilly to Further Enhance AI/ML Capabilities and Accelerate Development of New Oral Macrocycle Therapies
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers...
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines New offering expands Lilly Catalyze360's support for early-stage drug development INDIANAPOLI...
Eli Lilly And Company (LLY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Jacob Van Naarden - Executive VP & President of Lilly Oncol...
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S NVO and Eli Lilly And Co LLY achieve a combined market cap topping $900 billion. Celebrit...
Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs
Eli Lilly continues to do what it does best, which is to capture the obesity and type 2 diabetes treatment markets at an extremely rapid pace. So, sales of its flagship franchise called tirzepatide re...
Lilly's blood cancer drug meets main goal in late-stage study
Eli Lilly said on Monday its blood cancer treatment Jaypirca met the main goal in a late-stage study in patients who have not received prior treatment.
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-naïve CLL/SLL
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Top 50 High-Quality Dividend Stocks For September 2025
I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto...
Novo Nordisk Vs Eli Lilly: Novo A Clear Winner
Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment t...
Eli Lilly And Company (LLY) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY) 2025 Wells Fargo Healthcare Conference September 5, 2025 9:30 AM EDT Company Participants Patrik Jonsson - Executive VP & President of Lilly International Mike Czapar...
Lila Biologics Announces Collaboration with Lilly For Radioligand Therapy Discovery and Development
Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Diseases Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Disease...
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
The Breakthrough Therapy designation for olomorasib is based on data from the Phase 1/2 LOXO-RAS-20001 trial and Phase 3 SUNRAY-01 trial Updated efficacy and safety data for olomorasib will be present...